Urokinase. The 50 μL microclots was incubated with 10 μL of 0 to 50 000 IU/mL urokinase (u-PA; Medac, Hamburg, Germany) in 6% bovine serum albumin-phosphate-buffered saline (BSA-PBS; A 3059; Sigma) and 50 μL of pooled normal plasma; the final u-PA concentrations were 0, 16, 33, 65, 130, 260, 521, 1042, 2083, 4167, and 8333 IU/mL. Tissue-type plasminogen activator. The 50 μL microclots was incubated with 10 μL of 0 to 630 000 IU/mL tissue-type plasminogen activator (t-PA; Boehringer Ingelheim, Germany) in 6% BSA-PBS and 50 μL of pooled normal plasma; the final t-PA concentrations were 0, 0.2, 0.4, 0.8, 1.6, 3.3, 6.6, 13, 26, 52.5, 105, and 210 μg/mL.
I n emergency medicine, a physician is often confronted with a massive thrombotic embolism of the pulmonary arteries. Sometimes, there are only minutes to rescue the patient's life. The lifethreatening thrombus has to be eliminated either by surgery or by fibrinolysis. [1] [2] [3] In this article, it is verified that extremely activated plasmatic fibrinolysis is capable of destroying such a thrombus within minutes.
Materials and Methods
In all, 50 μL microclots was generated by addition of 100 μL 1563 mM CaCl 2 (Sigma, Deisenhofen, Germany) to 10 mL of pooled normal plasma (maintained at ≤6-hour room temperature when pooled and frozen at −80°C; containing 0.1 mg/mL plasminogen), and it was pipetted into F-well microtiter plates and incubated for 40 minutes (37°C, water bath).
A life-threatening thrombus in massive pulmonary embolism has to be eliminated within minutes. Extremely activated plasmatic fibrinolysis destroys such thrombi in time: 50 μL plasma clots were incubated with urokinase or tissue-type plasminogen activator and 50 μL pooled normal plasma. The microtiter plate clot lysis assay was performed. The time point at which 50% of the clot has been lysed is 4 minutes for 8333 IU/mL urokinase or an equimolar concentration of tissue-type plasminogen activator (52498 IU/mL = 105 μg/mL). The effective dose 50% at 5 minutes lysis time is about 800 nM (4320 IU/mL) urokinase or (27 220 IU/mL = 54 μg/mL) tissue-type plasminogen activator. Addition of plasminogen to the plasmatic clot supernatant improves thrombolysis if 65 IU/mL of urokinase acts for 10 minutes. The risk for severe intracranial hemorrhage in massive thrombolysis might be much lower than the lethality of a massive pulmonary embolism. Extremely activated plasmatic thrombolysis could be clinically indicated.
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The effective dose (ED 50 ) of u-PA-mediated and t-PA-mediated clot lysis was determined. The plasma supernatant was supplemented with 0.125 mg/mL of additional plasminogen (plgen + ; Chromogenix-Haemochrom, Essen, Germany; 1 mg/mL containing 8.2 mM lysine), the u-PA-mediated lysis was measured after 5 minutes and 20 minutes (37°C), and the ED 50 of u-PA/plgen + lysis was determined.
Clot Lysis Enhancement by Different plgen + +
In all, 50 μL microclots was incubated with 10 μL of 0 IU/mL or 65 IU/mL u-PA or 410 IU/mL t-PA in 6% BSA-PBS and 50 μL of pooled normal plasma supplemented with 0 to 0.25 mg/mL plgen + . The turbidity of the wells was determined after 10 minutes (37°C). Figure 4 shows that the ED 50 at 5 minutes lysis time is about 800 nM (4320 IU/mL) u-PA or (27 220 IU/mL = 54 μg/mL) t-PA.
Results and Discussion
The addition of plasminogen to the plasmatic clot supernatant improves thrombolysis if 65 IU/mL u-PA acts for 10 minutes (37°C); compared with less than 5% of clot that is lysed without plgen + , about 30% of the clot is lysed if 0.125 mg/mL plasminogen is added to normal plasma ( Figure 5 ). The real fibrinolysis enhancing efficiency of plasminogen has to be much higher because the plasminogen preparation used contained lysine, resulting into a final lysine concentration of 0.9 mM (the inhibitory concentration 50% of lysine against u-PA is 2.0 mM 5 ). The activity of an equimolar concentration of t-PA does not increase in presence of higher plasminogen concentrations. This might indicate that the plgen + /u-PA combination might be the ideal one for extremely activated thrombolysis.
Thus, in emergency medicine, the activator might be a physiological one, such as u-PA or t-PA, and might be given within few minutes and not within hours. 3 The fibrinolysis, especially that by urokinase, might be augmented by prior administration of plasminogen. 6 The risk for severe intracranial hemorrhage in massive thrombolysis is about 2%. 7, 8 Considering that the lethality of a massive pulmonary embolism might exceed 50%, the present in vitro simulation model suggests that extremely activated thrombolysis could be clinically indicated. Figure 5 . Clot lysis enhancement by plgen + . In all, 50 μL microclots was incubated with 10 μL 0 IU/mL or 65 IU/mL u-PA (•) or 410 IU/mL t-PA ( ) in 6% BSA-PBS and 50 μL pooled normal plasma supplemented with additional 0 to 0.25 mg/mL plasminogen. The turbidity of the wells was determined after 20 minutes (37°C). plgen + indicates additional plasminogen; u-PA, urokinase; t-PA, tissue-type plasminogen activator; BSA-PBS, bovine serum albumin-phosphate-buffered saline.
